CURE Pharmaceutical Holding Corp (OTCMKT:CURR) stock jumped 6% after the company announced that the USPTO office had issued it a notification indicating that US Patents No 11,179,331 is scheduled to be issued on November 23, 2021.
Trading Data
On Tuesday, CURR stock moved up 6.12% at $0.52 with more 71K shares, compared to its average volume of 101k shares. The stock has moved within a range of $0.5000 – 0.5500 after opening trade at $0.52.
Receives Patent Approval for Its CUREfilm Blue™ Technology
Notably, the patent entitled “Oral Soluble Film Containing Sildenafil Citrate,” covers the company’s CUREfilm Blue oral sildenafil citrate soluble film for erectile dysfunction treatment.
CUREfilm Blue delivers the active pharmaceutical ingredient (API) sildenafil citrate using CURE’s patented and novel CUREfilm fast-dissolving medicine delivery platform. The company is developing this exceptionally discrete, easy, and portable oral film soluble product for a better patient experience by thinking beyond conventional pharmaceutical delivery of tablets and solutions. The patent shows numerous key features of the CUREfilm Blue, including a balance of performance characteristics such as the early onset of action and rapid solubility and physical parameters like large mass and small thickness. Most importantly, one can use Curefilm Blue with or without water or beverage. So CURR is worth watching.
Technical Data
CURR stock is trading below the 20-Day and 50-Day Moving averages of $0.57 and $0.64 respectively. However, the stock is trading above 200-Day moving average of $0.75. The stock is down 25% in the past month.
